Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Klaria Pharma Holding ABFRA:6FN 9 3-Year EBITDA Growth Rate is 46.10% as of Mar. 2026. GuruFocus rates FRA:6FN with a GF Score™ of 9/100 and a GF Value™ of €0.03 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 809 Drug Manufacturers companies, Klaria Pharma Holding AB ranks better than 88.13% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 46.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 34.80% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Klaria Pharma Holding AB was 46.10% per year. The lowest was -32.40% per year. And the median was -0.10% per year.
Klaria Pharma Holding AB (FRA:6FN) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Klaria Pharma Holding AB 3-Year EBITDA Growth Rate Related Terms
FRA:6FN vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's 3-Year EBITDA Growth Rate falls into.
Klaria Pharma Holding AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 46.10% mean?
Klaria Pharma Holding AB (FRA:6FN) has a 3-Year EBITDA Growth Rate of 46.10% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Klaria Pharma Holding AB and its competitors. According to the industry distribution chart, Klaria Pharma Holding AB ranks #96 out of 809 companies in the Drug Manufacturers industry, placing it in the top 11.9%.
Is Klaria Pharma Holding AB's 3-Year EBITDA Growth Rate too high?
Klaria Pharma Holding AB's current 3-Year EBITDA Growth Rate is 46.10%. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Klaria Pharma Holding AB's value of 46.10% is 418% above this industry median. Based on the distribution chart, Klaria Pharma Holding AB ranks #96 out of 809 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 9/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #96 out of 809 companies for 3-Year EBITDA Growth Rate. This places Klaria Pharma Holding AB in the top 12% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 8.90. Klaria Pharma Holding AB's value of 46.10% is 418% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klaria Pharma Holding AB's current 3-Year EBITDA Growth Rate of 46.10% is 418% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Klaria Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current 3-Year EBITDA Growth Rate is 46.10%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.08 — trading 166.7% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 46.10% and 418% above the Drug Manufacturers industry median of 8.90. Klaria Pharma Holding AB's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current 3-Year EBITDA Growth Rate is 46.10% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.08 is trading 166.7% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
3-Year EBITDA Growth Rate: 46.10%
GF Value™: €0.03 vs. price of €0.08 (166.7% above fair value)
Industry Position: 418% above the Drug Manufacturers median (#96 of 809)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
9GF Score
Get the complete analysis for FRA:6FN
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 
